Bloomberg -- Edwards Lifesciences Corp. may double annual revenue and become a buyout target with U.S. approval of a $30,000 cardiac valve that can be implanted without open heart surgery.
Bloomberg -- Edwards Lifesciences Corp. may double annual revenue and become a buyout target with U.S. approval of a $30,000 cardiac valve that can be implanted without open heart surgery.